SL65.0155
SL65.0155 is a selective 5-HT4 receptor partial agonist (Ki = 0.6 nM; IA = 40-50% (relative to 5-HT)). It potently enhances cognition, learning, and memory, and also possesses antidepressant effects. SL65.0155 was in phase II clinical trials around 2004-2006 for the treatment of memory deficits and dementia but no new information has surfaced since and it appears to have been abandoned.
See also
References
This page contains text from Wikipedia, the Free Encyclopedia - https://wn.com/SL65.0155
Podcasts:
PLAYLIST TIME: